1 / 1

Acute Oncology Clinical Nurse Specialist Patient informed of Management plan

Hyponatraemia in Oncology: Magnitude of the problem: Proposed Management Algorithm for Syndrome of Anti Diuretic Hormone associated with Cancer A Joint Acute Oncology & Acute Medicine Project Bulusu V R, Jeffs Y P, Barclay C, Melvin A. Bedford Hospital Kempston Road, Bedford UK.

gayora
Download Presentation

Acute Oncology Clinical Nurse Specialist Patient informed of Management plan

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Hyponatraemia in Oncology: Magnitude of the problem: Proposed Management Algorithm for Syndrome of Anti Diuretic Hormone associated with Cancer A Joint Acute Oncology & Acute Medicine ProjectBulusu V R, Jeffs Y P, Barclay C, Melvin A. Bedford Hospital Kempston Road, Bedford UK Background: Hyponatraemia is defined as a serum Na+ of <135 mEq/l. SIADH secretion is a known metabolic complication of cancer resulting in hyponatraemia. Project designed to define the incidence of hyponatraemia and construct a management algorithm for SIADH. Traditional management of SIADH includes fluid restriction to < 1l/day, demeclocycline and hypertonic saline. Recently vasopressin-2 receptor antagonists have been introduced to treat SIADH. Methods: Serum sodium results from April to September 2011 extracted from the biochemistry database (N=31,420). Severe Hyponatraemia defined as serum sodium <125 mEq/l; results were coded against the requester’s speciality. Results: Severe hyponatraemia was documented in 447/31420, (1.4%) of all Na+ results. Biochemistry requests from Lung team (2.3%) and acute medicine team (3.3%) had the highest incidence. Full work up for SIADH was performed in <2%. We propose the following algorithm for cancer patients with SIADH. Management algorithm for SIADH in Oncology Hyponatraemia <135 mEq/l Serum Na+ <110mEq/l or acute neurological symptoms ITU Serum Na+ ≥125 mEq/l OBSERVE Hyponatraemia<125 mEq/l Serum Osmolality <270 mOsm Urine Osmolality >100 mOsmol Elevated Urinary Na+ >25 mEq/l Exclude ↓ T4 ↓ Cortisol Renal failure Euvolemic Acute Oncology & Endocrinology Jointly review management plan Acute Oncology Clinical Nurse Specialist Patient informed of Management plan SIADH • Information sheet for SIADH & consent • Review concomitant medications (drug interactions) • Oral Tolvaptan 15 mg od starting dose, ↑ to 60 mg as req • U/E LFTs on days 1, 3 and 5 • Continue Tolvaptan for 5-7 days & review • Specific anticancer treatment Conclusions: We propose a new management algorithm for the management of SIADH incorporating oral Tolvaptan, a vasopressin-2 receptor antagonist, avoiding the need for fluid restriction & demeclocyline. Patients with SIADH should be jointly managed by acute oncology and endocrinology specialist teams. vrbulusu@gmail.com

More Related